Interim results in clinical trials: Do we need to keep all interim randomised clinical trial results confidential?

Lung Cancer

Volumn 85, Issue 2, 2014, Pages 116-118

  Stephens, R J ^a   Langley, R E ^a   Mulvenna, P ^b   Nankivell, M ^a   Vail, A ^c   Parmar, M K B ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Evidence based medicine; Growth restriction intervention; Interim results; Non small cell lung cancer; Randomised clinical trials; Whole brain radiotherapy

Indexed keywords

ACCESS TO INFORMATION; BRAIN METASTASIS; BRAIN RADIATION; EVIDENCE BASED MEDICINE; HUMAN; INTERIM RESULT; LUNG NON SMALL CELL CANCER; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL SECRECY; PROFESSIONAL STANDARD; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; BRAIN NEOPLASMS; CONFIDENTIALITY; ETHICS; INTRAUTERINE GROWTH RETARDATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; PREMATURITY; RESEARCH ETHICS; SECONDARY; STANDARDS;

BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CONFIDENTIALITY; ETHICS, RESEARCH; EVIDENCE-BASED MEDICINE; FETAL GROWTH RETARDATION; GUIDELINES AS TOPIC; HUMANS; INFANT, PREMATURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84904120269     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.05.012     Document Type: Note

References (15)

1. Ellenberg S.S., Fleming T.R., DeMets D.L. Data Monitoring Committees in Clinical Trials: a Practical Perspective 2002, John Wiley, Chichester.
2. Abrams D.I., Goldman A.I., Launer C., Korvick J.A., Neaton J.D., Crane L.R., et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with Human Immunodeficiency Virus Infection. New Eng J Med 1994, 330:657-662.
3. Fleming T.R., Neaton J.D., Goldman A., DeMets D.L., Launer C., Korvick J., et al. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Syndr Hum Retrovirol 1995, 10:S9-S18. Insights from monitoring the CPCRA didanosine/zalcitabine trial.
4. Green S.J., Fleming T.R., O'Fallon J.R. Policies for study monitoring and interim reporting of results. J Clin Oncol 1987, 5:1477-1484.
5. Fleming T.R., Sharples K., McCall J., Moore A., Rodgers A., Stewart R. Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clin Trials 2008, 5:157-167.
6. Grant A.M., Altman D.G., Babiker A.B., Campbell M.K., Clemens F.J., Darbyshire J.H., et al. Issues in data monitoring and interim analysis of trials. Health Technol Assess 2005, 9(7).
7. Lilford R.J., Braunholtz D., Edwards S., Stevens A. Monitoring clinical trials - interim data should be publicly available. BMJ 2001, 323:441-442.
8. Langley R.E., Stephens R.J., Nankivell M., Pugh C., Moore B., Navani N., et al. Interim data from the Medical Research Council QUARTZ trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer?. Clin Oncol 2013, 25:e23-e30.
9. Lilford R. Formal measurement of clinical uncertainty: prelude to a trial in perinatal medicine. BMJ 1994, 308:111-112. for the Fetal Compromise Group.
10. Vail A., Hornbuckle J., Spiegelhalter D.J., Thornton J.G. Prospective application of Bayesian monitoring and analysis in an 'open' randomized clinical trial. Stat Med 2001, 20:3777-3787.
11. Spiegelhalter D., Freedman L.S., Parmar M.K.B. Bayesian approaches to randomized controlled trials. J Roy Stat Soc 1994, 157:357-416.
12. A randomised trial of timed delivery for the compromised pre-term fetus: short term outcomes and Bayesian interpretation. BJOG 2003, 110:27-32. The GRIT Study Group.
13. Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomized controlled trial. Lancet 2004, 364:513-520. The GRIT Study Group.
14. Cheng S.K., Dietrich M.S., Finnigan S., Dilts D.M. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP sponsored clinical trials. Clin Cancer Res 2011, 17:1947-1955.
15. Korn E.L., Freidlin B., Mooney M., Abrams J.S. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. J Clin Oncol 2010, 28:5197-5201.